Achieve Life Sciences, Inc.
ACHV Healthcare Biotechnology
In the quarter to June 2026, EPS fell 116.2%, free cash flow fell 19.0% and total debt rose 63.9%, each against the same quarter a year earlier.
Follow ACHV
Achieve Life Sciences, Inc. (ACHV) EV/Sales
As of 16 October 2026, Achieve Life Sciences, Inc. (ACHV) trades at a EV/Sales of 27.2×. Over the past ten years it has ranged from −3.1× (February 2016) to 39.6× (August 2026); the current reading is higher than 98% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2016 | 0.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2016 | −0.6× | — |
| Mar 2016 | −1.7× | — |
| Sep 2015 | −0.1× | — |
| Jun 2015 | −0.3× | — |
| 1 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IVA Inventiva S.A. Sponsored ADR compare | −0.1× |
| SANA Sana Biotechnology, Inc. compare | n/m |
| ANL Adlai Nortye Ltd. Sponsored ADR compare | n/m |
| ANNX Annexon, Inc. compare | n/m |
| IMMX Immix Biopharma, Inc. compare | n/m |
| FDMT 4D Molecular Therapeutics, Inc. compare | 5.6× |
| LXRX Lexicon Pharmaceuticals, Inc. compare | 12.8× |
| OABI OmniAb, Inc. compare | 14.0× |
| ACHV Achieve Life Sciences, Inc. | 27.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)